| Loss of PTEN promotes resistance to T cell–mediated immunotherapy W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... Cancer discovery 6 (2), 202-216, 2016 | 1297 | 2016 |
| BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma DT Frederick, A Piris, AP Cogdill, ZA Cooper, C Lezcano, CR Ferrone, ... Clinical cancer research 19 (5), 1225-1231, 2013 | 958 | 2013 |
| Toll-Like Receptor 8-Mediated Reversal of CD4+ Regulatory T Cell Function G Peng, Z Guo, Y Kiniwa, KS Voo, W Peng, T Fu, DY Wang, Y Li, ... Science 309 (5739), 1380-1384, 2005 | 953 | 2005 |
| Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion Y Hailemichael, Z Dai, N Jaffarzad, Y Ye, MA Medina, XF Huang, ... Nature medicine 19 (4), 465-472, 2013 | 464 | 2013 |
| PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines W Peng, C Liu, C Xu, Y Lou, J Chen, Y Yang, H Yagita, WW Overwijk, ... Cancer research 72 (20), 5209-5218, 2012 | 458 | 2012 |
| CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer Y Kiniwa, Y Miyahara, HY Wang, W Peng, G Peng, TM Wheeler, ... Clinical cancer research 13 (23), 6947-6958, 2007 | 449 | 2007 |
| Tumor-infiltrating γδ T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway G Peng, HY Wang, W Peng, Y Kiniwa, KH Seo, RF Wang Immunity 27 (2), 334-348, 2007 | 435 | 2007 |
| Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy T Cascone, JA McKenzie, RM Mbofung, S Punt, Z Wang, C Xu, ... Cell metabolism 27 (5), 977-987. e4, 2018 | 428 | 2018 |
| BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice C Liu, W Peng, C Xu, Y Lou, M Zhang, JA Wargo, JQ Chen, HS Li, ... Clinical cancer research 19 (2), 393-403, 2013 | 387 | 2013 |
| CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade L Chen, L Diao, Y Yang, X Yi, BL Rodriguez, Y Li, PA Villalobos, ... Cancer discovery 8 (9), 1156-1175, 2018 | 341 | 2018 |
| Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses W Peng, Y Ye, BA Rabinovich, C Liu, Y Lou, M Zhang, M Whittington, ... Clinical Cancer Research 16 (22), 5458-5468, 2010 | 224 | 2010 |
| Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer J Zhao, X Wen, L Tian, T Li, C Xu, X Wen, MP Melancon, S Gupta, B Shen, ... Nature communications 10 (1), 899, 2019 | 197 | 2019 |
| Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications GM Fischer, YN Vashisht Gopal, JL McQuade, W Peng, RJ DeBerardinis, ... Pigment cell & melanoma research 31 (1), 11-30, 2018 | 159 | 2018 |
| Tumor-associated galectin-3 modulates the function of tumor-reactive T cells W Peng, HY Wang, Y Miyahara, G Peng, RF Wang Cancer research 68 (17), 7228-7236, 2008 | 152 | 2008 |
| Development of immunotherapy combination strategies in cancer TA Yap, EE Parkes, W Peng, JT Moyers, MA Curran, HA Tawbi Cancer discovery 11 (6), 1368-1397, 2021 | 120 | 2021 |
| Enhanced differentiation of splenic plasma cells but diminished long-lived high-affinity bone marrow plasma cells in aged mice S Han, K Yang, Z Ozen, W Peng, E Marinova, G Kelsoe, B Zheng The Journal of Immunology 170 (3), 1267-1273, 2003 | 118 | 2003 |
| HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes RM Mbofung, JA McKenzie, S Malu, M Zhang, W Peng, C Liu, I Kuiatse, ... Nature communications 8 (1), 451, 2017 | 113 | 2017 |
| 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy G Han, G Yang, D Hao, Y Lu, K Thein, BS Simpson, J Chen, R Sun, ... Nature communications 12 (1), 5606, 2021 | 83 | 2021 |
| The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression L Huang, S Malu, JA McKenzie, MC Andrews, AH Talukder, T Tieu, ... Clinical Cancer Research 24 (14), 3366-3376, 2018 | 81 | 2018 |
| Anti-tumor activity mediated by CpG: the route of administration is critical Y Lou, C Liu, G Lizée, W Peng, C Xu, Y Ye, BA Rabinovich, ... Journal of immunotherapy (Hagerstown, Md.: 1997) 34 (3), 279, 2011 | 80 | 2011 |
Gregory LizéeProfessor, MD Anderson Cancer CenterVerified email at mdanderson.org
